Regulatory Sanofi receives FDA approval for Tzield in paediatric diabetes Pharmaceutical Business ReviewThe approval expands the previous indication from those aged eight and above and was granted under a priority review process.RegulatoryMetabolic & GLP-1Read full story pharminent April 23, 2026 (Last updated: April 23, 2026) Pharmaceutical Business Review The approval expands the previous indication from those aged eight and above and was granted under a priority review process. RegulatoryMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie opts for North Carolina to house $1.4bn manufacturing siteNext: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
